Form 4: Catalyst Pharma Chairman Boosts Stake, Receives Awards

Catalyst Pharmaceuticals Chairman Patrick J. McEnany acquired common stock and received new equity awards, increasing his beneficial ownership.

Summary

• Patrick J. McEnany, Chairman of the Board of Directors for Catalyst Pharmaceuticals, Inc. (CPRX), reported several transactions.
• On November 21, 2025, 1,775 shares of common stock were acquired directly by Mr. McEnany, bringing his total direct beneficial ownership to 4,283,477 shares. This acquisition resulted from the vesting and delivery of restricted stock units.
• On November 20, 2025, Mr. McEnany was granted 34,921 options to purchase common stock at an exercise price of $22.77, with an expiration date of November 20, 2032. These options are scheduled to vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Also on November 20, 2025, he was granted 10,540 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock upon vesting. These RSUs are also scheduled to vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• On November 21, 2025, 1,775 Restricted Stock Units vested and were converted into common stock. These RSUs were part of an award that vests in three equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027, with the first tranche delivered on November 21, 2025.
• Following these transactions, direct beneficial ownership of derivative securities includes 1,873,051 options to purchase common stock and 1,881,816 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing indicates a positive sentiment due to the Chairman's acquisition of common stock and the grant of new equity awards, aligning his interests with shareholders and demonstrating continued commitment to the company.

Positives

• Chairman Patrick J. McEnany increased his direct beneficial ownership of common stock by 1,775 shares, signaling confidence in the company's future.
• The grant of 34,921 new stock options and 10,540 Restricted Stock Units aligns management's interests with long-term shareholder value.
• The vesting schedules for the new equity awards extend through November 2028, indicating a sustained commitment from the Chairman.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's performance or strategy. It primarily reports past transactions and future vesting schedules for equity awards.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide broader industry context or competitive analysis.

Comparison to Industry Standards

• This filing reports standard equity compensation grants and vesting events for a public company executive.
• The specific terms, such as option exercise price and vesting schedules, are typical for executive compensation packages in the pharmaceutical industry, designed to incentivize long-term performance and retention.
• No specific comparable companies, projects, or results are mentioned in the filing for direct comparison.

Stakeholder Impact

• Shareholders: Positive signal of management confidence and alignment of interests through increased equity ownership and long-term incentive awards.

Next Steps

• Scheduled vesting of 34,921 options and 10,540 Restricted Stock Units in equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Scheduled vesting of the remaining tranches of the 1,775 Restricted Stock Units on November 21, 2026, and November 21, 2027.

Key Dates

Recommendation

The filing reports routine insider transactions, including the acquisition of common stock through RSU vesting and the grant of new equity awards to the Chairman. While these actions demonstrate management's confidence and align their interests with shareholders, a Form 4 alone typically does not provide sufficient fundamental information to warrant a 'buy' or 'sell' recommendation. It serves as a positive signal, reinforcing a 'hold' position for existing investors, but does not present new information that would drastically alter the investment thesis without further context on the company's financial performance or strategic outlook.

Keywords

Catalyst Pharmaceuticals, CPRX, insider transaction, Form 4, stock options, restricted stock units, beneficial ownership, Patrick J. McEnany, equity awards, director, chairman